H.R. 1840 · 115th Congress
Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017
- Stage
- In committee
- Sponsor
- Erik Paulsen
- Introduced
- 2017-03-30
- Latest action
- 2017-03-30 · Introduced in House
Summary
Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017
This bill amends the Internal Revenue Code to allow tax credits for 50% of the clinical testing expenses for: (1) infectious disease products that are intended to treat a serious or life-threatening infection, including one caused by an antibacterial or antifungal resistant pathogen or a qualifying pathogen listed by the Department of Health and Human Services as having the potential to pose a serious threat to public health; and (2) in-vitro diagnostic devices that identify in less than four hours the presence, concentration, or characteristics of a serious or life-threatening infection.